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An international survey identified 40 patients <20 years old
who underwent surgical implantation of an automatic im-
plantable cardioverter-defibrillator (AICD). There was a
history of aborted sudden cardiac death or sustained ven-
tricular tachycardia in 92.5% of these patients. Twenty-two
patients (55%) had structural heart disease; dilated and
hypertrophic cardiomyopathy were the most common diag-
noses. Eighteen patients (45 %) had primary electrical
abnormalities including seven with the congenital long QT
syndrome. There were no perioperative deaths associated
with device implantation. Concomitant drug therapy was
administered to 75% of the patients.
Since the first automatic implantable cardioverter-
defibrillator (AICD) was implanted in 1980 (1). defibrillator
therapy has become an important treatment approach for
patients who survive sudden cardiac death (2-8). with ap-
proximately 11.000 units implanted worldwide (Smutka M.
personal communication). Most of these implantations have
been in adults. with coronary artery disease (8) the predom-
inant underlying diagnosis.
Sudden cardiac death due to tachyarrhythmias has be-
come an increasingly recognized cause of death in young
patients (9-16). Because of the heterogeneity of underlying
cardiac diagnoses in these patients. a variety of therapeutic
strategies may be required (16). The application of the AlCD
to the young sudden cardiac death survivor represents one
logical therapeutic approach. However. there are few pub-
lished data that address the extension of defibrillator therapy
to the young patient (17). Therefore. this study was under-
taken to further characterize young patients who have
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Defibrillator discharge occurred in 70% of the patients,
with 17 patients (42.5 %) receiving at least one appropriate
shock. There were two sudden and two nonsudden deaths
at 28.2 months' median follow-up. Sudden death-free
survival rates by life table analysis at 12 and 33 months
were 0.94 and 0.88, respectively. Total survival rates at
12 and 33 months were 0.94 and 0.82, respectively. The
AICD represents an effective treatment approach for
young patients with life-threatening ventricular tachyar-
rhythmias.
(J Am Coli CardioI1990;16:896-902)
received an AICD and to examine surgical considerations
and outcome in these patients.
Methods
Study patients. To identify the population of patients who
were <20 years old at the time of AICD implantation the
Cardiac Pacemakers data base was utilized. Subjects were
noted and referred to only by registration number to protect
confidentiality. Implanting or attending physicians were con-
tacted directly or by questionnaire to obtain more detailed
data. Of 50 patients identified. detailed responses were
received regarding 40 patients (Appendix) who are the
subjects of this analysis. All patients underwent defibrillator
implantation between October 1980 and November 1989.
Device selection. The first patient received the original
automatic implantable defibrillator (AID) model, which
sensed only sinusoidal ventricular tachycardia or ventricular
fibrillation. Nine patients initially received the lntec AID-B
or AID-BR device. which became available in 1982. All
other patients received the CPI Ventak AICD. which be-
came generally available in 1986.
Definitions. For the purpose of this study, the following
definitions were used:
Sudden cardiac death: the abrupt cessation of respiratory
and circulatory function due to underlying cardiac disease.
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Figure I. Distribution of ages of 40 young patients who received an
automatic implantable cardioverter-defibrillator. The median age
was 15 years.
Sustained I'entricular tachycardia: ventricular tachycar-
dia >30 s in duration or requiring termination due to hemo-
dynamic deterioration.
Clinicall'entricular tach.vcardia: ventricular tachycardia
induced by programmed electrical stimulation that was ei-
ther clinically documented or was considered compatible
with the patient's clinical presentation.
Nonclinical I'entricular tachycardia: ventricular tachy-
cardia induced by programmed electrical stimulation that
had not been clinically documented and. in the opinion of the
responding physician. was not compatible with the patient's
clinical presentation.
Ventricular fibril/ation: random. chaotic electrical activ-
ity of the ventricles with no associated cardiac output.
Appropriate shock: a defibrillator shock that. in the
opinion of the responding physician. was delivered in re-
sponse to a sustained ventricular tachyarrhythmia.
Spurious shock: a defibrillator shock that. in the opinion
of the responding physician. was delivered for reasons other
than a sustained ventricular tachyarrhythmia.
Indeterminate slwck: a defibrillator shock that could not
be classified as appropriate or spurious.
Statistical analysis. All data are presented as median or
mean values ± SD unless otherwise specified. Life table
analysis of survival was performed by the Kaplan-Meier
method.
Results
Patient characteristics. The group consisted of 25 male
and 15 female patients with a median age of 15 years (range
8 to 19) (Fig. I). The median weight was 56 kg (range 30 to
86). The indications for device implantation were aborted
sudden cardiac death due to ventricular fibrillation or hy-
potensive ventricular tachycardia (n = 35). drug refractory
ventricular tachycardia (n = 2). syncope with inducible
monomorphic ventricular tachycardia at electrophysiologic
study (n == I) and a strong family history of sudden cardiac
FAMILIAL SD
(2)
Figure 2. Associated cardiovascular diagnoses. CHD = congenital
heart disease: DCM = dilated cardiomyopathy: HCM = hyper-
trophic cardiomyopathy: SD = sudden death: 1° VF = primary
ventricular fibrillation: Numbers in parentheses indicate number of
patients.
death and inducible ventricular fibrillation at the time of
electrophysiologic study (n = 2).
Associated cardiovascular diagnoses. Twenty-two pa-
tients had identifiable structural heart disease: the most
prevalent diagnosis was dilated or hypertrophic cardiomy-
opathy (\5 patients: Fig. 2). Four of the 22 patients had
congenital heart disease and three of the four had a history of
prior corrective surgery. One of the four patients had com-
plex anomalous pulmonary venous return associated with
dilated cardiomyopathy: one had transposition of the great
vessels with double outlet right ventricle and one had
transposition with a ventricular septal defect and pulmonary
stenosis. The fourth patient had isolated corrected transpo-
sition with congenital complete heart block for which a
pacemaker had previously been placed. In three other pa-
tients the diagnosis was arrhythmogenic right ventricular
dysplasia. Kawasaki's disease and mitral valve prolapse.
respectively.
The other 18 patients Iwd {/II underlying electrical abnor-
mality. Nine had primary ventricular fibrillation. seven had
congenital long QT syndrome and two had a strong family
history of sudden cardiac arrest.
Ventricular fil/lction. as estimated by angiographic or
echocardiographic techniques. was normal in 25 patients.
reduced in 7 and not available in 8.
Preimplant electrophysiologic study. Before defibrillator
implantation. 36 patients underwent an electrophysiologic
study. Sustained ventricular tachyarrhythmias were induced
in 20 patients including ventricular fibrillation in 13 and
ventricular tachycardia that was believed to represent the
clinical arrhythmia in 8 patients. Two patients had ventric-
ular tachycardia induced that was not believed to represent
clinical arrhythmia. No ventricular tachyarrhythmias were
induced in 16 patients.
Thirt.\' (If" the 35 surl'il"ors II( aborted .\udden death had
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Table 2. Concomitant Drug Therapy in 40 Patients
Table I. Profile of Shocks Delivered by the Implantable
Defibrillator in 40 Patients
in five patients. Lead fracture necessitating lead replacement
occurred in two patients and pocket erosion requiring gen-
erator site revision occurred in one patient.
Psycholo[?ic acceptance of the device has been difficult
j(Jr some patients. One patient dropped out of school be-
cause of psychologic difficulties. Two patients requested
device explantation including the patient with pocket ero-
sion, who refused AICD reimplantation after explantation of
the original device.
Profile of defibrillator discharges (Table 1). During a
median follow-up period of 29 months after AICD implanta-
tion. one or more defibrillator discharges occurred in 28
(70%) of the 40 patients. Seventeen patients (42.5%) experi-
enced at least one appropriate shock. whereas II (27.5%)
received only spurious or indeterminate shocks. Twelve
patients (30%) have experienced no defibrillator shocks. The
number of shocks experienced by each patient ranged from
I to 40 (mean 10.1 ± 10).
Concomitant drug therapy (Table 2). After defibrillator
placement. pharmacologic therapy was continued for 30
ventricular fibril/ation as the presenting arrhythmia. Ven-
tricular fibrillation was induced in 10 (33%) of the 30 patients
with documented ventricular fibrillation. Of the other 20, I
had sustained ventricular tachycardia induced, 16 (53%) had
no inducible arrhythmias and 3 did not undergo electrophys-
iologic study. Of the five survivors of sudden death with
hypotensive ventricular tachycardia as the presenting ar-
rhythmia, three had inducible ventricular tachycardia, one
had no arrhythmias induced and one did not undergo elec-
trophysiologic study. Both patients with drug-refractory
ventricular tachycardia and the patient with syncope had
sustained monomorphic ventricular tachycardia induced.
The two patients with a strong family history of sudden
death had inducible ventricular fibrillation.
Surgical considerations. The most common surgical ap-
proach was a lateral thoracotomy, which was used in 22
patients (56%). A midline sternotomy was used in 12 patients
(31%) and a subcostal or subxiphoid incision was used in 3
(8%) and 2 (5%) of the patients, respectively. Data with
regard to patch size were available for 36 patients. The
defibrillation lead configuration was small patch (10 cm2)-
small patch in 14 patients (39%), large patch (20 cm2)-small
patch in 12 patients (33%) and large patch-large patch in 2
patients (6%). A spring-patch configuration was used in
eight patients (22%); a large patch was used in five of the
eight patients receiving a spring-patch configuration. Epicar-
dial rate-sensing electrodes were used in 87% of the patients.
All patients had adequate defibrillation thresholds, which
ranged from 2to 20 J. Concomitant surgery included division
of an accessory pathway, coarctation repair, myocardial/
lung biopsy and left stellate ganglionectomy in one patient
each.
Concomitant pacemakers. Six (15%) of the patients also
received a pacemaker. Two of these had a bipolar dual
chamber unit, two had an antitachycardia pacemaker with
VVI backup, one had a VVIR unit and one had an AAI-MB
overdrive pacemaker for the management of recurrent atrial
flutter.
Early complications. Complications that occurred before
hospital discharge included pericardial effusion in two pa-
tients and phrenic paralysis, pneumothorax and hematoma
requiring transfusion in one patient each. One other patient
had tracheal stenosis that was attributed to prolonged intu-
bation after the patient's initial aborted sudden cardiac
death. Two patients had defibrillator system malfunctions
that were noted at the predischarge electrophysiologic
study. These included pulse generator failure that necessi-
tated generator replacement in one patient and excessive
defibrillation threshold that was corrected by changing from
a patch-patch to a spring-patch configuration in one other
patient.
Late complications. The most common problems experi-
enced after hospital discharge have been lead related. Over-
or undersensing of the patient's QRS complexes was noted
Discharge Category
Appropriate only
Appropriate and spurious
Appropriate and indeterminate
Spurious only
Spurious and indeterminate
Indeterminate only
None
Total
See text for definitions of discharge categories.
Drug Therapy
Antiarrhythmic drugs
Procainamide
Phenytoin
Quinidine
Disopyramide
Flecainide
Propafenone
Mexiletine + quinidine
Amiodarone
Total
AV node blockers
Beta-adrenergic blocking agents
Verapamil
Digoxin + beta-adrenergic
blocking agent
Total
AV = atrioventricular.
No. of Patients (%)
12 (30)
3 (7.5)
2 (5)
6 (15)
1(2.5)
4 (10)
12 (30)
40 (100)
No. of Patients (%)
1(2.5)
1(2.5)
1 (2.5)
2 (51
I (2.5)
I (2.5)
I (2.51
4 (10)
12 (30)
17 (42.51
30.5)
1 (2.5)
21 (52.5)
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Figure 3. Survival of 40 young patients who received an automatic
implantable cardioverter-defibrillator. A, Actuarial sudden death-
free survival. B, Total survival rate (see text for details). Numbers
indicate number of patients at each follow-up period.
(75%) of the 40 patients, prescribed either for rate control of
supraventricular rhythms or specific therapy to prevent
recurrent ventricular tachyarrhythmias. Six of seven pa-
tients with the congenital long QT syndrome continued
beta-adrenergic blocking therapy after defibrillator implan-
tation.
Long-term survival. There were a total of four deaths
during a median follow-up of 28.2 months. Two of these
deaths were sudden: one in a patient who was water skiing
against medical advice and the other in a patient who
sustained significant neurologic damage after her initial
cardiac arrest and whose parents were ambivalent regarding
intensity of treatment and failed to comply with AICD
generator replacement when it showed signs of battery
depletion.
There were two J1oJ1sudden deaths. One patient died of
progressive congestive heart failure and one other patient
died secondary to complications after cardiac transplanta-
tion.
Actuarial survival curves are shown in Figure 3. Sudden
12 18 H· 30 36
FOLLOW UP (Months)
42 48
cardiac death-free survival rates at 12 and 33 months were
0.94 and 0.88, respectively. Total survival at 12 and 33
months was 0.94 and 0.82, respectively.
Life-style considerations. To determine whether defibril-
lator therapy further impaired the patient's already limited
life-style, implanting physicians were asked whether driving
a car or informal or competitive athletics were permitted
(Fig. 4). Driving was allowed in 8 patients and was prohib-
ited in 14; at least two patients continued to drive against
medical advice. Competitive athletics were prohibited in 22
(76%) of 29 patients, whereas informal athletics were al-
lowed in 27 (84%) of 32 patients for whom information was
available. There was at least one pregnancy, resulting in the
delivery of a normal child. The mother received what
appeared to be an appropriate defibrillator shock during the
third trimester of pregnancy without apparent adverse con-
sequences to the fetus.
Discussion
The AICD can be effectively used in children and young
adults with a low surgical morbidity and a long-term out-
come similar to that of older patients (8). However, experi-
ence with the AICD in young patients is still quite limited
and the true long-term outcome of defibrillator therapy in
patients who may survive for decades is yet to be defined.
Nevertheless, the AICD offers an important therapeutic
option for young patients with life-threatening ventricular
tachyarrhythmias who have a relatively poor prognosis
unless successful antiarrhythmic therapy can be defined
(16,18).
Anatomic and surgical considerations. The patients in this
survey differ anatomically from adult patients with an im-
planted defibrillator, of whom approximately 75% have
underlying coronary artery disease (8). The majority of the
younger patients have either some form of cardiomyopathy
900 KRON ET AL.
DEFIBRILLATORS IN YOUNG PATIENTS
lACC Vol. 16. No.4
October 1990:896-902
or a primary electrical abnormality and thus no history of
prior cardiac surgery. Therefore, in most cases surgery can
be performed via a lateral thoracotomy. Although few of our
patients had complex congenital heart disease. they ap-
peared to tolerate defibrillator implantation without signifi-
cant additional morbidity. However, preoperative anatomic
evaluation of all patients undergoing AICD implantation is
appropriate to identify any potentially correctable lesions
that can be repaired at the time of surgery.
Patient size does not appear to he a significant issue, with
the majority of patients having epicardial rate-sensing and
defibrillation electrodes placed without difficulty. In some
cases, especially in patients with a history of prior cardiac
surgery, it may be necessary to utilize either transvenous
rate-sensing or defibrillation spring electrodes. However. in
most cases the added complexity of transvenous leads in
growing patients can be avoided. The weight of the CPI
model 1550 defibrillator is 235 g (19), which may present a
problem for smaller patients. It has been our practice to
utilize a subrectus generator position for these patients.
which has provided an acceptable cosmetic result and has
made the patient acceptance of the device less of an issue.
Role of preoperative eIectrophysiologic study and the man-
agement of patients with no inducible arrhythmias, It is
currently standard practice to perform preoperative electro-
physiologic studies in most patients undergoing defibrillator
implantation (20). These studies may be useful in defining
concomitant pharmacologic therapy, providing more accu-
rate device selection and programming and occasionally
identifying patients with correctable electrical abnormalities
such as Wolff-Parkinson-White syndrome. Preoperative
electrophysiologic studies may be less useful in patients with
the long QT syndrome (2L22) and in patients with dilated
cardiomyopathy in whom programmed ventricular stimula-
tion has an uncertain prognostic and therapeutic role (23,24).
A prohlematic area regarding electrophysiologic testing
is the management ofpatients with no inducihle I'entricular
tachyarrhythmias. Depending on the series reported and the
status of left ventricular function. these patients mayor may
not have a favorable long-term prognosis (25-28). In rela-
tively young patients without severe underlying heart dis-
ease, it may be fair to measure prognosis in decades. The
relatively good prognosis of 5% per year arrhythmia recur-
rence in adults with no inducible tachyarrhythmias and
relatively normal hemodynamic status may not be accept-
able in children (20.28). In the present series 16 patients had
no inducible ventricular arrhythmias at the time of electro-
physiologic study and 2 other patients had what were con-
sidered to be nonclinical arrhythmias induced. In follow-up.
3 (17%) of these 18 patients experienced 2 to 14 appropriate
discharges and 3 others experienced 1 to 17 indeterminate
defibrillator discharges. Recently it was suggested (29) that
many indeterminate shocks may actually be appropriate. If
these findings are corroborated. then 6 (33%) of the 18
patients in this series with noninducible arrhythmia would
already have had appropriate use of their devices. Because
patients remain at continued risk of arrhythmia recurrence.
perhaps other patients with no inducible arrhythmias will
eventually experience shocks as well.
Role of concomitant drug therapy, Young patients with an
implanted defibrillator may continue to require drug therapy
either to decrease the frequency of recurrent ventricular
tachyarrhythmias or to prevent inappropriate shocks sec-
ondary to sinus tachycardia or supraventricular tachyar-
rhythmias. The frequency of antiarrhythmic therapy appears
to be similar to that in adult patients (6,8), although it is
likely that the need for atrioventricular node blocking agents
may be more frequent for younger patients. It has been our
practice to treat younger patients with beta-adrenergic
blocking therapy routinely after AICD implantation but to
avoid specific antiarrhythmic therapy for patients who have
had infrequent ventricular tachyarrhythmias. Antiarrhyth-
mic therapy can be added to the regimen of patients receiv-
ing relatively frequent AICD shocks to improve patient
comfort and safety, as well as to enhance device longevity.
Life-style and psychosocial considerations. The majority
of patients and families have been very accepting of defibril-
lator therapy and most patients have been able to resume
normal daily activities. However. some patients and families
have found it difficult to comply with some of the life-style
and follow-up restrictions. For the most part. however, the
restrictions are not imposed by the presence of the AICD but
rather by the patients' arrhythmias and the known suscepti-
bility to recurrence. Inability to follow recommendations has
contributed to a fatal outcome in some patients.
It is unclear whether young A/CD patients should he
allowed to dril'c. Some patients will have syncope with their
arrhythmia before their device is activated; even in those
who remain conscious, the discharge itself could render
them accident prone. In this series there was no consensus
among implanting physicians as to whether driving should be
permitted. Although we have taken an inconsistent ap-
proach, we currently discourage driving for these patients
and. even when driving is permitted, we forbid freeway use.
These issues make it essential that young patients and
their families be counseled and given extensive psychologic
support before and after implantation. It may be appropriate
not to place a defibrillator in the rare patient who is unlikely
to adjust to the restrictions on life-style imposed by the
AICD.
Future considerations. Although the AICD appears to
represent an important advance in the management of young
patients with life-threatening arrhythmias. there clearly is a
need for new devices that will facilitate the broader applica-
tion of implantable defibrillator therapy to the younger
patient (30). Potential developments include smaller devices
with enhanced generator longevity. nonthoracotomy sys-
tems, improved telemetry capabilities, combination devices
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October 1990:896-902
KRON ET AL.
DEFIBRILLATORS IN YOUNG PATIENTS
901
with antitachycardia and bradycardia pacing capabilities and
tachycardia detection algorithms that can distinguish su-
praventricular from ventricular tachyarrhythmias. Little is
known about the long-term effects of patch electrodes on the
growing heart or the effective longevity of these electrodes.
Longitudinal follow-up of these patients will identify prob-
lems and help facilitate the long-term management of the
young survivor of sudden cardiac death who has undergone
defibrillator implantation.
We thank John Davis for preparation of the manuscript. Cynthia Morris. PhD
for assistance in statistical analysis and John H. McAnulty. MD for review of
the manuscript.
Appendix
Survey responders
University of Alabama Hospital, Birmingham, AL: Andrew Epstein. MD.
Baptist Memorial Hospital, Memphis, TN: Owen Hartness. MD.
Barnes Hospital, St. Louis, MO: Bruce Lindsay. MD.
Cedars Sinai Hospital, Los Angeles, CA: Daniel Oseran. MD.
Children's Hospital, Philadelphia, PA: Victoria Veller. MD. Francis
Marchlinski. MD.
University Hospitals of Cleveland, OH: Richard Henthorn. MD.
University of Colorado, Denver, CO: David Mann. MD.
Columbia Presbyterian Medical Center. New York. NY: 1. Thomas
Bigger. Jr.. MD. Mary Kral. PA-e. Alan Hordof. MD. Henry
Spotnitz. MD.
Foothills Provincial General Hospital, Calgary. Alberta. Canada: Anne
Gillis. MD.
Good Samaritan Hospital. Los Angeles. CA: David Cannom. MD.
Harborview Medical Center. Seattle. WA: Gust Bardy. MD.
Henry Ford Hospital. Detroit. MI: Charles Webb. MD.
H6pital Cantonal Universitaire. Geneva, Switzerland: M. Zimmerman. MD.
Hospital of the University of Diisseldorf. Diisseldorf. Federal Republic of
Germany: Martin Borggrefe. MD.
Lariboisiere Hospital. Paris. France: Philippe Coumel. MD.
Loyola University. Chicago. IL: David Wilber. MD.
Massachusetts General Hospital, Boston, MA: Jeremy Ruskin. MD.
Millard Fillmore Hospital, Buffalo, NY: Donald Switzer. MD.
Milwaukee City Medical Complex, Milwaukee. WI: Paul Troup. MD.
Moffitt Hospital, San Francisco, CA: Jerry Griffin. MD.
Monteliore Hospital, New York. NY: Gordon Kritzer. MD. John Fisher. MD.
M!. Sinai Hospital. Milwaukee, WI: Mohammed Jazayeri. MD.
Oregon Health Sciences Uninrsity. Portland. OR: John McAnulty. MD. Jack
Kron. MD. Michael Silka. MD.
Sinai Hospital. Baltimore. MD: Enrico Veltri. MD. Linda J. Schenker. RN.
Stanford University. Palo Alto, CA: Roger Winkle. MD. Jan Peterson. R
Charles Swerdlow. MD.
University Hospital. London, Ontario. Canada: AIjun Sharma. MD.
Vanderbilt University Hospital. Nashville. TN: John Lee. MD.
Washington Hospital Center: Edward Platia. MD.
Western Pennsylvania Hospital. Pittsburgh. PA: Barrv Alpert. MD.
University of Virginia, Charlottesville. VA: Bruce Lerman. MD. John
DiMarco. MD.
Westfalische Wilhelms·Universitat, Munich. Federal Republic of Germany:
Gunter Breithardt. MD.
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